The facility will be mass spec-focused and comprise a service contract lab for developing protein tests and a CAP- and CLIA-certified lab for offering them.
The firm said total revenues rose to $461.4 million from $431.7 million in the first quarter of 2018, beating analysts' consensus estimate of $450.1 million.
The company posted revenues of $513.9 million for the quarter compared to $530.7 million in Q1 2018, below the average Wall Street estimate of $545.3 million.
A study from the University of Montreal adds to findings indicating the approach can help reduce sample complexity and interferences in quantitative work.
The tool is the latest such package to be released as the field continues to move towards open searching, which could significantly expand breadth of analysis.
The work suggests DIA can be a rapid way to confirm the outcome of CRISPR experiments while looking at the downstream effects of the targeted alterations.
The company is planning a 2020 commercial launch of PNNL's SLIM IMS tech, which could significantly improve the sensitivity and throughput of mass spec assays.
Developed in collaboration with Waters and Labcyte, the platform enables applications including high-throughput drug screening and metabolomic profiling.
The study made use of a high-resolution mass spec approach developed by University of Minnesota scientists that allows for untargeted discovery of DNA adducts.
The approach allows researchers to profile the protein complexes present in a sample in much the same way they have the individual peptides and proteins.
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
